

Immune Checkpoint Inhibitor Synthetic Data: HDR UK **Medicines Programme Resource**

Data range for infographic: 01/2015 - 09/2023

Other extended time periods are available on request

A synthetic dataset featuring patient-level information for 683 cancer patients treated with checkpoint inhibitors, including demographics, primary cancer diagnoses, details of ICI treatments, and other clinical records during hospital admissions.

Demographic

The dataset includes:

- Young adults **2%** (ages <34)
- Adults **44%** (ages 35-64)
- Elderly **54%** (ages 65+)

63% of immune checkpoint inhibitor (ICI) treated patients are male and 37% of ICI patients are female. 5% 1% 1% 84% 1% 8%












Asian Black Mixed White Other **Specified**

Inhibitor categories



● PD-1 inhibitors ● CTLA-4 inhibitors ● PDL-1 inhibitors

Immune checkpoint inhibitors

49% of patients are treated with Nivolumab, a PD-1 inhibitor. Followed by 41% of patients treated with Pembrolizumab and 27% with Ipilimumab.

Top 5 patients cancer diagnoses

28

of upper lob,

bronchus and

luna

124



37

Secondary neoplasm





27

and cerebral

meninges



25

of trunk

Cancer types

- 63% diagnosed with neoplasm or melanoma of skin
- 14% diagnosed with secondary neoplasm

Other cancer types are available.

Inpatient care

- **15,177** Hospitalized spells
- **683** Patients Admitted to Critical Care
- **86,000** Days of Hospital Data
- **8-hour** Median In-Hospital Length of Stay
- **26%** In-Hospital Mortality Rate
- **70%** of Patients Surviving 12 Months After Discharge
 - Median National Early Warning Score: 1

Top 3 Consultation directorate

525

Oncology

502



Emergency Medicine

General Medicine

Top 4 Therapy treatment




Physiotherapy



Dietetics



Occupational... therapy



language

therapy

85

Medical imaging

4,070

Radiology



CT



366



Fluoroscopy



Angiography

Other medical imaging are available.

Medical procedures

Top 5 medical procedures are:



of

medicati...







given



to organ...





written under fluids advice imaging control

Other procedures are available.